NEWS & INSIGHTS

News & Insights

Latest industry trends and NewsPicks commentary

01

Corporate News

Official announcements from Yap Inc. — partnerships, awards, funding, and more.

Press Release

Yap signs a service agreement with Italy's Icarus — adapting an AI that takes the first call at medical institutions for Japan

Yap Inc. has signed a definitive service agreement, dated August 25, 2026, with Icarus S.r.l. (brand name: Icarus Technology), an Italian company providing a voice assistant in which AI answers calls to medical institutions. Following the memorandum of understanding signed on May 28, 2026, Yap now begins the research needed to adapt the service to Japanese healthcare settings. The name for the Japanese market is "Kyoko AI." No launch date in Japan has been decided at this time.

Read the full release
Press Release

Yap Signs Memorandum of Understanding with Italy's Icarus S.r.l.

Yap Inc. has signed a Memorandum of Understanding (MoU) on a business partnership with Icarus S.r.l. (product brand: Icarus Technology), a company based in Sardinia, Italy. The MoU follows business development meetings in Tokyo, with the support of the Italian Trade Agency (ITA) and Regione Autonoma della Sardegna, and through SusHi Tech Tokyo, hosted by the Tokyo Metropolitan Government, and the venue of Tokyo Innovation Base. Icarus provides a multilingual AI voice assistant that automates patient phone reception for clinics; together the two companies aim to combine this with Yap's healthcare business and AI capabilities to expand in the Japanese market.

Read the announcement on LinkedIn
Press Release

Yap Signs Partnership Agreement with Indonesian Digital Biobank Asa Ren

Yap Inc. has signed a business partnership agreement with Asa Ren, an Indonesian digital biobank company. Asa Ren operates Southeast Asia's first AI-powered digital biobank, integrating clinical and genomic data across diverse ethnic groups to advance personalized medicine and drug discovery. The two companies aim to expand awareness and adoption of Asa Ren's digital biobank.

Read the press release (PR TIMES)
Press Release

Yap Signs Import Agreement with Bangladesh's UniMed UniHealth — First Bangladeshi Pharma to Enter Japan

Yap Inc. has signed an import agreement with UniMed UniHealth Pharmaceuticals Limited of Bangladesh. The agreement marks the first entry of a Bangladeshi pharmaceutical company into the Japanese market, beginning with Novotin, a biotin-based nutritional supplement.

Read the press release (PR TIMES)
02

Industry Monthly

A monthly digest of pharmaceutical policy, market, and technology, based on public sources.

Monthly6 items

August 2026 Industry Monthly

Japan's seven major domestic pharmaceutical companies posted revenue of 3.08 trillion yen (up 17.3% year on year) and operating profit of 611.5 billion yen (up 29.0%) for April-June 2026, while the domestic market grew 3.7% to 2.99 trillion yen over the same period. Meanwhile, IQVIA Japan data shows foreign-affiliated companies' share of the domestic market reached 49.3% in 2025, with commentators pointing to a possible crossing of the halfway mark during 2026. Reporting also emerged that some approved medicines have yet to launch while awaiting pricing decisions, putting the relationship between market growth and pricing policy in focus.

Read the report
Monthly7 items

July 2026 Industry Monthly

Japan's four major pharmaceutical wholesalers are projected to record their lowest operating profit margin in five years at 1.19% for FY2027 (ending March 2027), down 0.11 percentage points year-on-year, prompting each company to pursue earnings recovery and business diversification. Meanwhile, the Japan Research Institute (JRI) published a report proposing a shift to unit-of-use dispensing that could cut dispensing costs by over 1 trillion yen annually and unlock the professional potential of Japan's 200,000 community pharmacists.

Read the report
Monthly11 items

June 2026 Industry Monthly

The FY2027 drug-price revision drew opposing pulls: the fiscal council called for full implementation, while the growth-strategy council set a target of world-level growth for the patented-drug market. Also this month: drug-loss concerns from U.S. pricing policy, a CEO change at Takeda, and Japan's first BTK inhibitor for urticaria.

Read the report
Monthly7 items

May 2026 Industry Monthly

This month: a stable-supply subsidy, new-drug pricing at Chuikyo, an ¥11.8 trillion domestic market, and reimbursement for an iPS-derived therapy.

Read the report
03

NewsPicks Insights

Healthcare commentary shared by CEO Masaya Yamamoto on NewsPicks.

Platform

Filter by Tag

NewsPicksSeptember 14, 2026

ドラッグストア客単価上昇の構造的背景 ― OTC保険外化と産業再編

What stands out in the latest data is the combination of a slight decline in customer traffic alongside rising spend per visit. Tsuruha Group (pre-merger) posted a 1.3% drop in same-store customer count against a 4.3% rise in average transaction value, while Sugi Pharmacy recorded a 1.9% traffic decline paired with a 6.6% jump in spend—a consistent pattern across multiple chains. Beyond straightforward price inflation, I suspect shifts in the purchasing profile driven by in-store dispensing operations may be a contributing factor, though I present this as inference rather than established fact, since causal analysis is absent from the companies' disclosed data. As a structural backdrop, policy moves to exclude OTC-equivalent drugs from insurance coverage would push more purchases to out-of-pocket spending, lifting per-visit revenue while simultaneously risking suppressed healthcare-seeking behavior—an external variable that doesn't appear in the reported figures yet is too significant to ignore as a driver of industry consolidation. The combined Tsuruha entity, spanning some 5,657 stores, is steadily taking on the character of local community infrastructure integrating dispensing, OTC retail, and health consultation. How it reconciles economies of scale with the quasi-public function of community healthcare will be the defining test going forward.

Drug RetailOTC & Pharmaceutical PolicyHealthcare Infrastructure
Read more
NewsPicksSeptember 12, 2026

次世代原発×AI電力需要 ― ヘルスケア・創薬への構造的影響

The emergence of next-generation nuclear reactors—including small modular reactors (SMRs)—as leading candidates for U.S.-bound investment is driven by the surging power demand of AI data centers. I view this not merely as an energy policy discussion, but as a structural shift with direct implications for healthcare and life sciences. Drug discovery AI, medical image analysis, and genomic research platforms all depend on massive computational resources, meaning the stability and decarbonization of power infrastructure is increasingly determining the competitive attractiveness of R&D locations. For Japanese biotech ventures and medical AI startups seeking to participate in global R&D competition, the geopolitics of energy infrastructure can no longer be ignored. That said, significant uncertainty remains around SMR commercialization timelines and actual power delivery schedules. As investment into the U.S. accelerates under the framing of a technology supremacy race, the key question is how to manage the risk of expectations running ahead of implementation—and whether the relevant government ministries can engage with concrete, actionable roadmaps.

Energy PolicyMedical AI & Drug DiscoveryUS-Japan Investment & Geopolitics
Read more
NewsPicksSeptember 8, 2026

梅毒治療薬不足 ― サプライチェーン集中リスクと政策設計の課題

The prolonged shortage of benzathine benzylpenicillin—the sole standard treatment for syphilis—laid bare a structural vulnerability in Japan's infectious disease response. A single equipment failure at a manufacturing facility translated almost immediately into nationwide clinical constraints, precisely because production is concentrated in too few sites while demand continues to rise. This is not an isolated incident; it should serve as a catalyst for rethinking the procurement and stockpiling framework for infectious disease treatments as a whole. Complicating matters further, doxycycline—the suggested alternative—is restricted to patients with penicillin allergies, leaving clinicians with little room to maneuver. The real question now is whether authorities can move swiftly on emergency measures such as expanding the approved indications for alternatives and pursuing international procurement, while also building a policy architecture that distributes manufacturing risk before the next crisis strikes.

Infectious Disease ControlPharmaceutical Supply ChainPublic Health Policy
Read more
NewsPicksSeptember 4, 2026

熱中症対策の本質 ― 気温より社会制度の穴を埋めよ

The Japan Meteorological Association forecasts that broad regions—including Kanto, Tokai, Kinki, Kyushu, and Okinawa—will face 'strict alert' or even 'danger' level heat through the first half of September, and the pattern of prolonged late-summer heat is not unique to this year. Yet the core issue, in my view, lies less in temperature itself than in gaps within our social systems. As European heat waves have repeatedly demonstrated, the isolation of elderly people and the absence of welfare-check infrastructure dramatically elevate mortality risk. In Japan, a growing number of elderly people living alone have air conditioners but cannot use them effectively due to anxiety over electricity bills or difficulty operating the units—meaning installation rates alone paint a misleading picture. As this article rightly points out, nighttime heatstroke is closely tied to housing conditions and air-conditioner use, so addressing the economic and cognitive barriers that prevent that use is precisely where government and local communities must focus. Even as weather forecasting grows more sophisticated, the monitoring networks needed to translate that information into behavioral change have not kept pace. We need to deliberately design solutions that distinguish between what technology can handle and what requires human networks.

Heatstroke PreventionElderly Care & MonitoringSocial Infrastructure
Read more
NewsPicksAugust 26, 2026

筋トレ・ゲートボールと認知症リスク低下 ― 観察研究の解釈と政策への示唆

The prospective observational findings showing a significant reduction in dementia risk associated with resistance training and gateball are intriguing, yet residual confounding—such as frequency of social participation and baseline physical and cognitive function at the time individuals took up each activity—cannot be ruled out. Those who manage to make these activities a habit may already have higher physical function and health awareness, making it difficult to fully dismiss selection bias; reading the results as straightforward evidence that 'these specific sports work' should be avoided. That said, what concerns me is how public health authorities, who currently find it difficult to drill down to the level of specific activity types in their exercise recommendations, should interpret this kind of sport-specific risk data. The differences in risk by activity type revealed in this study could serve as one input for refining future guidelines, but a single observational study is not yet sufficient to drive policy design. I would like to see reproducibility confirmed across multiple prospective and intervention studies before these findings are reflected in the way specific activities are prescribed.

Dementia PreventionExercise & Physical ActivityPublic Health Policy
Read more
NewsPicksAugust 22, 2026

在宅テック介護の成長 ― 恩恵格差と地域連携が普及の分岐点

The 10-million-yen move-in fee now common at Tokyo nursing homes signals that senior housing has entered the realm of asset-allocation decisions—but the explosive growth of home-based tech care reflects something deeper: a cultural shift in where people want to age, not merely a difference in price point. What deserves close attention is the uneven distribution of that technology's benefits. Sensing devices, remote monitoring, and AI-driven condition alerts are genuinely advancing, yet they remain theoretical without the right family support, living environment, and communications infrastructure in place—raising serious questions about how far these tools can reach rural seniors living alone. From a care-continuity standpoint, for home tech care to function as a genuine 'place to live and die,' it must be architecturally integrated with visiting physicians and home-visit nursing teams. The real inflection point for adoption will not be product sophistication, but whether the solution can be embedded into local care teams on the ground.

Home Care TechnologyCare Access InequalityMedical-Care Integration
Read more
Page 1 / 12